These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35456923)

  • 1. Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus.
    Kim YC; Lücke AC; López-Camacho C; Kümmerer BM; Reyes-Sandoval A
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
    Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
    J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells.
    Abbo SR; Nguyen W; Abma-Henkens MHC; van de Kamer D; Savelkoul NHA; Geertsema C; Le TTT; Tang B; Yan K; Dumenil T; van Oers MM; Suhrbier A; Pijlman GP
    J Virol; 2023 Mar; 97(3):e0160122. PubMed ID: 36883812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses.
    Powers JM; Haese NN; Denton M; Ando T; Kreklywich C; Bonin K; Streblow CE; Kreklywich N; Smith P; Broeckel R; DeFilippis V; Morrison TE; Heise MT; Streblow DN
    PLoS Negl Trop Dis; 2021 Apr; 15(4):e0009308. PubMed ID: 33793555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro disease.
    Mota MTO; Costa VV; Sugimoto MA; Guimarães GF; Queiroz-Junior CM; Moreira TP; de Sousa CD; Santos FM; Queiroz VF; Passos I; Hubner J; Souza DG; Weaver SC; Teixeira MM; Nogueira ML
    Sci Rep; 2020 Mar; 10(1):5306. PubMed ID: 32210270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an Enzyme-Linked Immunosorbent Assay To Detect Antibodies Targeting Recombinant Envelope Protein 2 of Mayaro Virus.
    Fumagalli MJ; de Souza WM; Romeiro MF; de Souza Costa MC; Slhessarenko RD; Figueiredo LTM
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30787146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following Coemergence.
    Fischer C; Bozza F; Merino Merino XJ; Pedroso C; de Oliveira Filho EF; Moreira-Soto A; Schwalb A; de Lamballerie X; Netto EM; Bozza PT; Sarno M; Brites C; Gotuzzo E; Talledo M; Drexler JF
    mSphere; 2020 Feb; 5(1):. PubMed ID: 32024703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection Pattern of Mayaro Virus in Aedes aegypti (Diptera: Culicidae) and Transmission Potential of the Virus in Mixed Infections With Chikungunya Virus.
    Kantor AM; Lin J; Wang A; Thompson DC; Franz AWE
    J Med Entomol; 2019 Apr; 56(3):832-843. PubMed ID: 30668762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential.
    Webb EM; Azar SR; Haller SL; Langsjoen RM; Cuthbert CE; Ramjag AT; Luo H; Plante K; Wang T; Simmons G; Carrington CVF; Weaver SC; Rossi SL; Auguste AJ
    Sci Rep; 2019 Dec; 9(1):20399. PubMed ID: 31892710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
    López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity of silymarin against Mayaro virus and protective effect in virus-induced oxidative stress.
    Camini FC; da Silva TF; da Silva Caetano CC; Almeida LT; Ferraz AC; Alves Vitoreti VM; de Mello Silva B; de Queiroz Silva S; de Magalhães JC; de Brito Magalhães CL
    Antiviral Res; 2018 Oct; 158():8-12. PubMed ID: 30076863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mayaro virus pathogenesis and immunity in rhesus macaques.
    Weber WC; Labriola CS; Kreklywich CN; Ray K; Haese NN; Andoh TF; Denton M; Medica S; Streblow MM; Smith PP; Mizuno N; Frias N; Fisher MB; Barber-Axthelm AM; Chun K; Uttke S; Whitcomb D; DeFilippis V; Rakshe S; Fei SS; Axthelm MK; Smedley JV; Streblow DN
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011742. PubMed ID: 37983245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of anti-chikungunya single-domain antibodies in transgenic
    Webb EM; Compton A; Rai P; Chuong C; Paulson SL; Tu Z; Weger-Lucarelli J
    Front Microbiol; 2023; 14():1189176. PubMed ID: 37378291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E2 glycoprotein holds key residues for Mayaro virus adaptation to the urban Aedes aegypti mosquito.
    Cereghino C; Roesch F; Carrau L; Hardy A; Ribeiro-Filho HV; Henrion-Lacritick A; Koh C; Marano JM; Bates TA; Rai P; Chuong C; Akter S; Vallet T; Blanc H; Elliott TJ; Brown AM; Michalak P; LeRoith T; Bloom JD; Marques RE; Saleh MC; Vignuzzi M; Weger-Lucarelli J
    PLoS Pathog; 2023 Apr; 19(4):e1010491. PubMed ID: 37018377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mayaro virus: a forest virus primed for a trip to the city?
    Mackay IM; Arden KE
    Microbes Infect; 2016 Dec; 18(12):724-734. PubMed ID: 27989728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity by an engineered DNA vaccine for Mayaro virus.
    Choi H; Kudchodkar SB; Reuschel EL; Asija K; Borole P; Ho M; Wojtak K; Reed C; Ramos S; Bopp NE; Aguilar PV; Weaver SC; Kim JJ; Humeau L; Tebas P; Weiner DB; Muthumani K
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007042. PubMed ID: 30730897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.